StockData
Camp4 Therapeutics Corp logo

Camp4 Therapeutics Corp (CAMP) stock

CAMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3057% above fair value
$3.80−0.29 (-7.09%)

Close on Nov 13, 2026Market cap $238.46MP/E –Yield 0.00%

Earnings

Camp4 Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 5, 2026
Q3 FY2026 · estimated, during market hours
Revenue, Q3 FY2025
$795.00K
EPS, Q3 FY2025
-$0.55
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Camp4 Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 5, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 13, 2026during market hours–––Release
Q1 FY2026ended Mar 31, 2026May 7, 2026during market hours–––Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025during market hours$795.00K–-$0.55Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025during market hours–––Release
Q1 FY2025ended Mar 31, 2025May 13, 2025during market hours–––Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025during market hours–––Release
Q3 FY2024ended Sep 30, 2024Nov 21, 2024during market hours–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Camp4 Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Camp4 Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Camp4 Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. 8-K exhibit EX-99.1
    Update
  2. 8-K exhibit EX-99.2
    Update
  3. CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
    Results
  4. CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
    Update
  5. CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
    Update
  6. CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
    Update
  7. 8-K exhibit EX-99.2
    Update
  8. CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
    Results
  9. CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
    Update
  10. 8-K exhibit EX-99.2
    Update
  11. 8-K exhibit EX-99.1
    Update
  12. CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
    Update
  13. CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
    Results
  14. CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
    Update
  15. CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
    Update

See a number that looks wrong?